共被期刊论文引用了4次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 外周血磷脂酰肌醇蛋白聚糖-3检测在原发性肝癌诊断中的意义显示文摘目的探讨外周血磷脂酰肌醇蛋白聚糖-3(GPC3)检测在原发性肝癌诊断中的意义。方法应用酶联免疫吸附试验检测80例原发性肝癌患者、78例肝内良性占位病变患者和40例健康对照者外周血GPC3蛋白水平,了解GPC3蛋白在各组中的阳性率,探讨GPC3蛋白诊断原发性肝癌的敏感性和特异性。结果健康对照组血清GPC3蛋白水平为(196.76±112.24)pg/mL,肝内良性占位组为(248.56±123.35)pg/mL,原发性肝癌组为(678.23±325.22)pg/mL。原发性肝癌组血清GPC3蛋白水平高于肝内良性占位组和正常对照组(F=18.76,P<0.01)。根据ROC曲线,若外周血GPC3蛋白诊断原发性肝癌的界值为412.6 pg/mL,则敏感度为63.2%,特异度为89.3%,健康对照者GPC3蛋白阳性率为2.50%,肝内良性占位病变组阳性率为14.1%,原发性肝癌组阳性率为65.0%。各组间血清GPC3蛋白阳性率统计学差异有显著性意义(χ2=40.28,P<0.01)。若AFP诊断肝癌的截止值为400 ng/mL,AFP的阳性率为46.3%,联合检测AFP和GPC3的阳性率提高至77.5%。结论 GPC3蛋白可作为原发性肝癌诊断及鉴别诊断的重要指标之一。联合检测GPC3和AFP可能提高原发性肝癌的诊断敏感性。 | 吴诗品 刘真真 杨智 | 2010 | 中国现代医学杂志2010，20，21： | 6 |
| 2 | 肝细胞肝癌血清标志物的研究进展显示文摘肝癌在中国是最常见的恶性肿瘤之一,其病死率居恶性肿瘤的第3位。血清标志物的检测是早期诊断、复发监测和评估预后的有效方法。血清标志物包括蛋白质抗原、相关酶和同工酶、肿瘤相关基因等几类。作者综述了血清标志物在肿瘤早期诊断、疗效评价、复发监测、预后评估等方面的研究进展,并介绍近年来新出现的一些新的标志物如AFP mRNA、TERT mRNA以及它们在预后评估、复发监测上可能会起到的重要作用。 | 傅央波 陆枫林 | 2011 | 东南大学学报(医学版)2011，30，4： | 4 |
| 3 | 细胞因子与蛋白类标志物在原发性肝细胞癌诊断、疗效评估及复发、转移中的意义显示文摘目前对于原发性肝癌(primaryhepaticcarcino.ma,PHC)的诊断、疗效评估、复发及转移意义最大的是甲胎蛋白(AFP),但我国有30%-40%患者AFP为阴性,因此寻找AFP以外的PHC诊断、疗效观察及治疗后提示复发、转移的标志物成为近年研究重点。本文就此细胞因子及蛋白类标志物的研究进展做一综述。 | 钟嘉玮 王健 | 2012 | 江西医药2012，47，7： | 4 |
| 4 | Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria显示文摘Liver transplantation(LT) for hepatocellular carcinoma(HCC) has been established as a standard treatment in selected patients for the last two and a half decades. After initially dismal outcomes, the Milan criteria(MC)(single HCC ≤ 5 cm or up to 3 HCCs ≤ 3 cm) have been adopted worldwide to select HCC patients for LT, however cumulative experience has shown that MC can be too strict. This has led to the development of numerous expanded criteria worldwide. Morphometric expansions on MC as well as various criteria which incorporate biomarkers as surrogates of tumor biology have been described. HCC that presents beyond MC initially can be downstaged with locoregional therapy(LRT). Post-LRT monitoring aims to identify candidates with favorable tumor behavior. Similarly, tumor marker levels as response to LRT has been utilized as surrogate of tumor biology. Molecular signatures of HCC have also been correlated to outcomes; these have yet to be incorporated into HCC-LT selection criteria formally. The ongoing discrepancy between organ demand and supply makes patient selection the most challenging element of organ allocation. Further validation of extended HCCLT criteria models and pre-LT treatment strategies are required. | Mohammed Elshamy Federico Aucejo KV Narayanan Menon Bijan Eghtesad | 2016 | World Journal of Hepatology2016，8，21： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员